 |
인쇄하기
취소
|
LG Life Sciences to conduct phase I trial of novel diabetic agent
LG Life Sciences announced on October 25 that it will conduct Phase I test of a new dipeptidyl peptidase IV (LC15-0444) for the treatment of type II diabetes.
In type II diabetes, either the pancreas does not produce sufficient insulin or the body fails to respond properly to insulin.
LG diabetes program has been selected as a part of the Bio-Star Project promoted by the Korean Ministry o...
In type II diabetes, either the pancreas does not produce sufficient insulin or the body fails to respond properly to insulin.
LG diabetes program has been selected as a part of the Bio-Star Project promoted by the Korean Ministry o...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.